A medical resident is presenting a recent multicenter, randomized controlled trial at journal club. The trial evaluated a novel medication, neprastatin, for the prevention of acute exacerbations in patients with severe chronic obstructive pulmonary disease (COPD). The study enrolled 5,000 patients, with 2,500 randomly assigned to receive daily neprastatin and 2,500 assigned to receive a placebo. At the end of the 2-year follow-up period, the published abstract states that 150 patients in the placebo group experienced an acute COPD exacerbation, compared to 100 patients in the neprastatin group.
Based on the results presented in the abstract, what is the number needed to treat (NNT) with neprastatin to prevent one acute COPD exacerbation?
Answer: 50 patients